Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4
Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4